Substance / Medication

Selective serotonin re-uptake inhibitor

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

13 trials linked to this intervention

13
Total Trials
0
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Selective serotonin re-uptake inhibitors for premature ejaculation in adult men.
Sathianathen Niranjan J, Hwang Eu Chang, Mian Ruma et al. · Cochrane Database Syst Rev · 2021
PMID: 33745183Meta-AnalysisFull text (PMC)
[Efficacy and safety of selective serotonin re-uptake inhibitors in the treatment of premature ejaculation: a systematic evaluation].
Huang Xiao-ke, Lu Yi-ping, Luo Shun-wen et al. · Zhonghua Nan Ke Xue · 2009
PMID: 19452699Meta-Analysis
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).
Soomro G M, Altman D, Rajagopal S et al. · Cochrane Database Syst Rev · 2008
PMID: 18253995Meta-AnalysisFull text (PMC)
Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches.
Moja P L, Cusi C, Sterzi R R et al. · Cochrane Database Syst Rev · 2005
PMID: 16034880Meta-Analysis
Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans.
Berardelli R, Margarito E, Ghiggia F et al. · J Endocrinol Invest · 2010
PMID: 20414043RCT
Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy.
Woo Young Sup, Bahk Won-Myong, Jeong Jong-Hyun et al. · Psychiatry Clin Neurosci · 2013
PMID: 23683152Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Substance with serotonin re-uptake inhibitor mechanism of action (substance)
SNOMED CT
373225007
UMLS CUI
C0360105

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
13
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.